Small doses of vincristine sulfate produced dramatic improvement in patients with far-advanced reticulum cell sarcoma which previously had been resistant to other forms of therapy. The maximal initial dose was 25μg/kg body weight weekly; maintenance levels have been as low as 5μg/kg biweekly. This dosage schedule permitted prolonged courses of therapy and minimized toxicity, thus providing sustained antitumor effect. In one patient with disseminated reticulum cell sarcoma refractory to alkylating agents and irradiation, a 17-month course of therapy was tolerated without toxicity. Death, due to unrelated causes, occurred 29 months after initiation of vincristine; no tumor was found at autopsy. It is suggested that vincristine, given in small doses for weeks or months, is a systemic agent worthy of consideration for the primary therapy of generalized reticulum cell sarcoma.
Yount WJ, Finkel HE. Treatment of Refractory Reticulum Cell Sarcoma With Low Doses of Vincristine Sulfate. JAMA. 1966;197(7):535-538. doi:10.1001/jama.1966.03110070059016